Brainomix

Brainomix, an Oxford-based developer specializing in AI imaging tools for stroke and lung fibrosis, has secured an additional £4.8 million in an extension to its Series C funding round. This new capital will be used to expand the company's US operations and accelerate the deployment of its AI imaging platforms, Brainomix 360 Stroke and e-Lung, across hospitals.

Summary of transaction details:

• Value: £4.8 million
• Sector: Healthcare & Biotech
• Advisor: N/A
• Key Entities: Brainomix (Target); Parkwalk Advisors, Hostplus (via IP Group Hostplus Innovation Fund), Modi Ventures (Investors)
• Location: Oxford, UK (Target company base)

Note: The investment highlights continued support from existing investors and the entry of a new US-based investor, underscoring strong confidence in Brainomix's innovative AI solutions for critical medical conditions and its growth trajectory in key markets.